Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 13 hot stocks to buy with the highest upside potential.
Dyne Therapeutics Inc. (DYN)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 5,172,000 | $101,164,320 | +46% | 0.15% |
| 2. | Orbis Investment Management William B. Gray | 4,801,928 | $93,925,712 | 0.39% | |
| 3. | Siren L.L.C. Raymond Debbane | 3,502,941 | $68,517,526 | -26% | 2.04% |
| 4. | Perceptive Advisors Joseph Edelman | 3,478,944 | $68,048,145 | +544% | 1.21% |
| 5. | Armistice Capital Steven Boyd | 3,249,708 | $63,564,288 | +7% | 0.76% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.11 | 100,000 | $911,000.00 | 242,179 | 2025-07-14 | Filing | |
| $33.09 | 7,200 | $238,248.00 | 8,000 | 2024-09-04 | Filing | |
| $32.57 | 800 | $26,056.00 | 800 | 2024-09-04 | Filing | |
| $33.09 | 7,200 | $238,248.00 | 8,000 | 2024-09-04 | Filing | |
| $32.57 | 800 | $26,056.00 | 800 | 2024-09-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.72 | 2,662 | $55,156.64 | 196,877 | 2025-12-05 | Filing | |
| $20.72 | 880 | $18,233.60 | 87,510 | 2025-12-05 | Filing | |
| $20.72 | 144 | $2,983.68 | 94,729 | 2025-12-05 | Filing | |
| $13.41 | 2,640 | $35,402.40 | 199,539 | 2025-09-05 | Filing | |
| $13.41 | 144 | $1,931.04 | 94,873 | 2025-09-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,887,722 | $271,603,659 | 0.12% | |
| 2. | 11,215,565 | $219,376,451 | 0% | |
| 3. | 11,190,838 | $218,892,793 | 0% | |
| 4. | 9,130,465 | $178,591,895 | 20.64% | |
| 5. | 6,692,745 | $130,910,092 | 0% |
News See All
13 Hot Stocks to Buy with the Highest Upside Potential
On average, equities are expected continue to deliver positive results in 2026, this time with greater breadth across sectors, styles, and regions, compared to the other periods of the recent bull market...
Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry
As of the February 12 closing, Dyne Therapeutics (NASDAQ:DYN) held a strongly bullish consensus view. Of the 9 analysts covering the stock, 7 assigned Buy ratings and 2 issued Hold ratings.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (NASDAQ:DYN) is among the 14 best booming stocks to buy right now, with returns of over 23% in the last three months.
14 Best Booming Stocks to Buy Right Now
In a report released on January 9, Goldman Sachs said that it expects the index to rally 12% in 2026.
Why Analysts See a Huge Upside for Dyne Therapeutics (DYN)
As of the December 19 closing, the consensus analyst sentiment towards Dyne Therapeutics (NASDAQ:DYN) remains bullish.
15 Most Promising Mid-Cap Healthcare Stocks Under $50
Traditionally, healthcare stocks have been considered defensive, offering strong immunity to business cycles.
Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the high short interest stocks to buy right now.
11 High Short Interest Stocks to Buy Right Now
On December 8, Bob Doll, Crossmark Global Investments CEO and CIO, joined CNBC’s ‘Squawk on the Street’ to discuss the latest market trends and his expectations for the Fed.
Hedge Fund Resource Center